Internal Medicine, Hematology & Oncology · Oklahoma City, OK
NPI
1649275827
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
13301 N Meridian Ave, Ste 501
Oklahoma City, OK, 73120
Phone (405) 752-0871
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.6M
241,320 services
Medicare patients, 2024
506
Average age 75
Drug cost, 2024
$5.1M
2,224 prescriptions
Company payments, 2025
$3,054
From 49 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert E Reynolds was code J1453 (injection, fosaprepitant, 1 mg), 28,350 times for 36 patients. In total Robert E Reynolds billed 241,320 services in 103 codes, and Medicare paid $5.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 28,350 | 36 | $0.11 | $3,174 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,600 | 18 | $44.73 | $877K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 18,200 | 11 | $0.06 | $1,008 |
| J0897 Injection, denosumab, 1 mg | Office | 10,860 | 30 | $20.59 | $224K |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,105 | 12 | $0.08 | $551 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 5,600 | 47 | $15.69 | $88K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,178 | 66 | $0.09 | $457 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,880 | 13 | $6.28 | $18K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,783 | 48 | $0.66 | $1,844 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,357 | 17 | $0.07 | $173 |
| 99213 Office E&M - Established | Office | 1,666 | 461 | $65.22 | $109K |
| 96413 Chemotherapy Administration | Office | 715 | 90 | $92.83 | $66K |
| 96375 Injection Administration | Office | 652 | 67 | $11.15 | $7,268 |
| J9045 Injection, carboplatin, 50 mg | Office | 502 | 18 | $2.82 | $1,413 |
| 96372 Injection Administration | Office | 499 | 77 | $10.57 | $5,275 |
By year: 2022 $3.5M for 137,628 services; 2023 $4.3M for 160,710 services; 2024 $5.6M for 241,320 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,458 | 306 | $7.56 | $11K |
| 36415 Venipuncture Blood Collection | 359 | 139 | $8.36 | $3,000 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert E Reynolds prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 168 prescriptions and refills. In total Robert E Reynolds wrote 2,224 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 168 | 168 | 39 | $5,392 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 148 | 148 | 23 | $5,001 |
| Anastrozole Generic | 128 | 207 | 31 | $2,228 |
| Eliquis Apixaban | 98 | 106 | 13 | $61K |
| Prednisone Generic | 75 | 88 | 25 | $369 |
| Abiraterone Acetate Generic | 59 | 59 | Under 11 | $96K |
| Ondansetron Odt Ondansetron | 56 | 56 | 28 | $695 |
| Hydroxyurea Generic | 56 | 98 | 13 | $1,367 |
| Furosemide Generic | 53 | 61 | 18 | $144 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 52 | 54 | 35 | $662 |
| Potassium Chloride Generic | 45 | 65 | 12 | $557 |
| Dexamethasone Generic | 41 | 48 | 18 | $663 |
| Oxycodone Hcl Generic | 40 | 40 | Under 11 | $594 |
| Morphine Sulfate Er Morphine Sulfate | 39 | 39 | 11 | $1,412 |
| Fentanyl Generic | 38 | 38 | Under 11 | $3,664 |
Brand drugs: 493 claims; generic drugs: 1,731 claims; opioid claims: 499.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert E Reynolds $3,054 ($3,054 in general payments such as food, travel and fees) from 49 companies. The largest payer was Janssen Biotech, Inc. with $284.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 11 | $284 |
| Merck Sharp & Dohme LLC MRK | 9 | $200 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $190 |
| Pfizer Inc. PFE | 9 | $181 |
| Abbvie Inc. ABBV | 8 | $154 |
| Genzyme Corporation SNY | 5 | $149 |
| GlaxoSmithKline, LLC. GSK | 7 | $128 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $125 |
| Gilead Sciences, Inc. GILD | 6 | $122 |
| Alexion Pharmaceuticals, Inc. AZN | 4 | $113 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.